Navigation Links
Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:11/16/2007

ticipating in assessing bavituximab have extensive experience in conducting mid and late stage cancer studies that adhere to FDA and international standards, and we look forward to working with them to ensure the timely conduct of this important Phase II trial."

Tumor response in this new study will be evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) standards.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with metastatic breast cancer is currently undergoing regulatory review in India. A protocol for a Phase II trial of bavituximab in combination with the chemotherapy drugs paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) is also under regulatory rev
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years ... their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas ... other. Following the ceremony was a reception, with music by the Moonlight Serenade ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... higher learning, announced today that its RN to BSN and Master of ... awarded full accreditation through June 2020 from the Commission on Collegiate Nursing ...
(Date:8/4/2015)... ... August 04, 2015 , ... Lightning ... at its Denver facility that will usher in a new standard of sticker ... Labels more effectively meet its twin objectives of quality and quantity without ...
(Date:8/4/2015)... Arbor, MI and Topeka, KS (PRWEB) , ... ... ... Information Network (KHIN) announced today their partnership to make the Isabel Symptom Checker ... Isabel Symptom Checker provides consumers a mechanism to check their symptoms in an ...
(Date:8/3/2015)... SC (PRWEB) , ... August 04, 2015 , ... ... published the first-ever Guidelines for Oral-Systemic Thermography.* , The new internationally peer-reviewed Guidelines ... performance of dental and systemic health infrared imaging, in evaluating patients with dental-oral ...
Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3
... EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: EPCT) ... present a company overview at the BMO Capital,Markets ... at 11:00 a.m.,Eastern Time. The conference will be ... City on December 4th and 5th. Mr. Talley ...
... Ind., Nov. 28 Conseco, Inc. (NYSE:,CNO) said today that ... by Long Term Care Group, Inc. (LTCG) for certain,back-office functions ... Run-off segment. Conseco announced earlier this year that it was,considering ... will assume responsibility for the customer call center and the ...
... Special ... and exclusive performances from Cyndi Lauper, Indigo ... YORK, Nov. 28 SIRIUS Satellite Radio,(Nasdaq: SIRI ) today announced ... an exclusive broadcast event on SIRIUS OutQ,109, the nation,s first and only ...
... WASHINGTON, Nov. 28 Today, Lung Cancer,Alliance-Massachusetts ... Cancer. The Report Card gauges the progress being ... Massachusetts. LCA-MA is a chapter of,Lung Cancer Alliance ... cause of cancer deaths nationally, as,well as among ...
... hepatitis liver disease, study finds , , WEDNESDAY, Nov. 28 ... boost the number of clotting cells, called platelets, in ... researchers report. , The new drug is called eltrombopag, ... idiopathic thrombocytopenic purpura (ITP) were able to use the ...
... Risk of developing colorectal cancer is known to ... analysis of 26 studies, involving over 25,000 participants shows ... distinct patterns of genetic inheritance. A team of researchers, ... their findings today in Atlanta at the American Association ...
Cached Medicine News:Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 2Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 3Health News:Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer 2Health News:Drug May Help Reverse Clotting Deficiency 2Health News:Drug May Help Reverse Clotting Deficiency 3Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 2Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 3
(Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
... NEW YORK, Feb. 2, 2011 Reportlinker.com announces that ... catalogue: US Prebiotics Industry ... report analyzes the US And European markets for Prebiotics ... is further analyzed by the following product segments: Mannan-Oligosaccharide ...
... Feb. 2, 2011 H. D. Smith recently announced ... strategic planning and business development, Robert Appleby to corporate ... vice president marketing.  These appointments are the latest organizational ... address evolving customer needs. Joseph ...
Cached Medicine Technology:US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7H. D. Smith Aligns Leadership Positions to Fill Three Senior Roles 2
Designed to safely and easily removing a cataract nucleus, round serrated handle, dull finish....
Round handle dull finish. For right handed surgeon....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Medicine Products: